CRISPR/Cas9: research advances in hematopoietic stem cell transplantation

Hui Yang,Jian-wei Zhu,Hui-li Lu

DOI: https://doi.org/10.3969/j.issn.2095-4344.0631

2018-01-01

Abstract:BACKGROUND: The CRISPR/Cas9 gene editing system was derived from a bacterial adaptive system mediated by the Clustered Regularly Interspaced Short Palindrome Repeats (CRISPR) and CRISPR‐associated proteins (Cas). Hematopoietic stem cells (HSCs) are easy to isolate and capable of self‐renewal and differentiation into different cell types, and have been successfully applied in the treatment of hematological malignancies and severe autoimmune diseases. In vivo and in vitro HSCs editing using the CRISPR/Cas9 system is a research trend that improves the therapeutic effect of HSCs transplantation, and has great clinical potential. OBJECTIVE: To review the disease therapeutics, delivery systems, gene editing and clinical application of CRISPR/Cas9 in HSCs transplantation. METHODS: The key words of “hematopoietic stem cells, CRISPR/Cas9, gene editing, delivery” in Chinese and English were used to search CNKI, PubMed and online databases respectively for relevant articles published from 2012 to 2018. After initial screening, the 61 eligible articles were further analyzed, summarized and concluded. RESULTS AND CONCLUSION: The simple and efficient gene editing ability of CRISPR/Cas9 can be applied to edit HSCs in vitro and in vivo and assist the clinical achievements of HSCs transplantation, which can reconstitute the life‐long repair of hematopoietic system in the blood and immune systems in patients with hematopoiesis deficiencies. The limited delivery vehicles of CRISPR/Cas9 system remain to be further studied and optimized. In addition, the ethical and safety issues of CRISPR/Cas9 system in clinical research of HSCs need to be considered. Funding: the National Natural Science Foundation of China, No. 81273576; Shanghai Scientific and Technological Innovation Project, No. 17431904500